Expanding the possibilities of using sodium-glucose cotransporter 2 inhibitors in patients with heart failure-Reference-Cited by-同舟云学术

Expanding the possibilities of using sodium-glucose cotransporter 2 inhibitors in patients with heart failure

Published:2024 Issue:3 Volume:77 Page:585-590
ISSN:0043-5147
Container-title:Wiadomości Lekarskie
language:en
Short-container-title:Wiad Lek

Author:

Rоsul Мaryana М.¹,Bletskan Мyroslava М.¹,Ivano Nataliya V.¹,Rudakova Svitlana O.¹

Affiliation:

1. UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE

Abstract

Aim: To study the potential mechanisms of the beneficial cardiovascular effects of sodium-glucose cotransporter 2 (SGLT-2) inhibitors, the possibilities of improving the treatment and prognosis of patients with acute heart failure (HF) during their use. Materials and Methods: The data analysis of literary sources has been conducted regarding the results of existing studies evaluating the clinical benefit and safety of SGLT-2 inhibitors in patients with acute heart failure. Conclusions: The peculiarities of the pharmacological action of SGLT-2 inhibitors and the obtained research results expand the possibilities of using this group of drugs, demonstrating encouraging prospects in improving the prognosis of patients hospitalized with acute heart failure.

Publisher

ALUNA

Reference35 articles.

1. 1. Joshi SS, Singh T, Newby DE et al. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021;107(13):1032-38. doi: 10.1136/heartjnl-2020-318060.

2. 2. Levy D, Kenchaiah S, Larson MG et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397-402. doi: 10.1056/NEJMoa020265.

3. 3. Tromp J, Bamadhaj S, Cleland JG et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Glob Health. 2020;8(3):e411-e422. doi: 10.1016/S2214-109X(20)30004-8.

4. 4. McMurray JJ, Packer M, Desai AS et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure. N Engl J Med. 2014;371(11):993-1004. doi: 10.1056/NEJMoa1409077.

5. 5. McMurray JJ, Solomon SD, Inzucchi SE et al. DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008. doi: 10.1056/NEJMoa1911303.